elacestrant shows improved pfs in patients with er-positive/her2-negative metastatic breast cancer
Published 1 year ago • 410 plays • Length 3:24Download video MP4
Download video MP3
Similar videos
-
2:06
elacestrant significantly prolongs pfs for er /her2- metastatic bc without prior chemotherapy pts
-
4:05
camizestrant may be superior to fulvestrant in patients with hr-positive, her2-negative bc
-
0:46
update of emerald by duration of cdk4/6i in metastatic setting: elacestrant v soc in er /her2- mbc
-
2:03
emerald: elacestrant vs. soc for patients with er her2- metastatic breast cancer
-
4:39
serd vs investigator’s choice of endocrine monotherapy for er /her2-advanced/mbc
-
3:01
assessing elacestrant in ctdna-positive patients with er breast cancer
-
2:46
ameera-3: amcenestrant does not improve pfs in er /her2- breast cancer
-
7:08
selective oestrogen receptor degraders as treatment for er positive/her2 negative advanced/metas...
-
1:27
emerald: elacestrant vs physicians choice in er /her2- breast cancer
-
0:50
fda approves elacestrant (orserdu) for er-positive, her2-negative, esr1-mutated breast cancer
-
4:34
lasofoxifene vs fulvestrant for locally advanced/metastatic er /her2- breast cancer: elaine trial
-
5:40
trastuzumab deruxtecan doubles pfs in metastatic breast cancer with low her2 expression
-
7:06
everolimus extends pfs for hr positive, her2 negative breast cancer
-
6:55
mafalda oliveira, sabcs 2022: camizestrant vs fulvestrant for advanced er her2- breast cancer
-
3:22
managing recurrent metastatic er /her2- breast cancer
-
2:29
window of opportunity elipse trial: elacestrant in postmenopausal women with er her2-/ early bc
-
1:17
key trial updates in serds in er /her2- breast cancer from sabcs 2022
-
34:12
new and emerging agents in her2-negative metastatic breast cancer: implications for practice
-
1:17
comment: phase 3 study shows her2 therapy clinically meaningful for metastatic breast cancer pts